Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15.4Revenue (TTM) $M0.7Net Margin (%)-2,646.7Altman Z-Score-40.2
Enterprise Value $M15.1EPS (TTM) $-1.0Operating Margin %-2,574.7Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-2,646.4Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales16.85-y EBITDA Growth Rate %--Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-127.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-259.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.0ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with BIOC

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BIOC is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BIOC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HALE DAVID FDirector 2016-05-04Buy50,000$1-38view
Neff Edward A.Director 2016-05-04Buy100,000$1-38view
Gerhardt BruceDirector 2016-05-04Buy25,000$1-38view
Reiss Claire10% Owner 2016-05-04Buy614,273$1-38view
Wilson Margaret FayeDirector 2015-02-13Buy4,000$1.25-50.4view
ROYSTON IVORDirector 2015-02-13Buy12,000$1.25-50.4view
Neff Edward A.Director 2015-02-13Buy40,000$1.25-50.4view
Nall Michael W.CEO & President 2015-02-13Buy12,000$1.25-50.4view
HUEBNER BRUCE ADirector 2015-02-13Buy12,000$1.25-50.4view
HALE DAVID FChairman 2015-02-13Buy40,000$1.25-50.4view

Quarterly/Annual Reports about BIOC:

    News about BIOC:

    Articles On GuruFocus.com
    Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

    More From Other Websites
    Biocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference... Jul 25 2016
    Biocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference... Jul 25 2016
    ETF’s with exposure to Biocept, Inc. : July 21, 2016 Jul 21 2016
    GlaxoSmithKline (Egypt) : Neutral outlook but great fundamentals Jul 20 2016
    GlaxoSmithKline (Egypt): Price momentum supported by strong fundamentals Jul 19 2016
    BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 07 2016
    Biocept Gets Japanese Patent Covering Microchannel And Antibody Capture Jul 05 2016
    Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture Jul 05 2016
    Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture Jul 05 2016
    BIOCEPT INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 29 2016
    Biocept Comments on Reimbursement Provisions in CMS' Final PAMA Rule Jun 29 2016
    Biocept Comments on Reimbursement Provisions in CMS' Final PAMA Rule Jun 29 2016
    BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jun 17 2016
    Coverage initiated on Biocept by ROTH Capital Jun 06 2016
    Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test May 31 2016
    Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test May 31 2016
    ETF’s with exposure to Biocept, Inc. : May 26, 2016 May 26 2016
    BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... May 26 2016
    High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two... May 25 2016
    High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two... May 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)